Erythrocyte membrane encapsulated gambogic acid nanoparticles as a therapeutic for hepatocellular carcinoma
Ruijie Liu,Li He,Maoyu Liu,Lu Chen,Jun Hou,Jianyou Shi,Lan Bai,Ruijie Liu,Li He,Maoyu Liu,Lu Chen,Jun Hou,Jianyou Shi,Lan Bai
DOI: https://doi.org/10.1016/j.cclet.2022.05.089
IF: 9.1
2023-01-01
Chinese Chemical Letters
Abstract:Gambogic acid (GA) is a potential clinical anticancer drug that can exert antitumor effects via various molecular mechanisms. Notwithstanding, GA's low water solubility, poor stability, short half-life, and unavoidable toxic side effects have significantly hampered its clinical application. Erythrocyte membrane-coated nanoparticles (RBCM-NPs) improve drug's physicochemical properties, biocompatibility, and pharmacokinetic behaviors, allowing for long-term drug circulation and passive targeting. In this study, a novel biomimetic drug delivery system (DDS) against hepatocellular carcinoma was prepared by covering RBCM on GPP-NPs (GA-loaded mPEG-PLA NPs) to develop the RBC@GPP-NPs. In comparison to RBCM-free nanoparticles and free GA, RBC@GPP-NPs improved the drug's water solubility, stability, safety, and anti-tumor activity in vivo. We expect that this bionic nanoparticle composite can expand the clinical applicability of GA and provide a feasible solution for the research and development of GA's nano-formulation.
chemistry, multidisciplinary